Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Clinical trial NCT06655818 · TERMINATED

Trial details

NCT number: NCT06655818
Sponsor: GlaxoSmithKline
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Multiple Myeloma

Start date: 2021-03-09
Primary completion: 2024-02-14
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.